Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.
|
|
- Beryl Wilcox
- 7 years ago
- Views:
Transcription
1 Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel
2 Disclaimer: The opinions expressed in this presentation are those of the author, and do not reflect those of F. Hoffmann-La Roche Ltd.
3 Overview of presentation Causality and case processing Guidance from regulators and CIOMS Naranjo algorithm at Roche Language to express uncertainty Reaching definitive conclusions about drug-event pairs Conclusions Final thoughts
4 Causality and case processing Spontaneous case reports Reporter s assessment of causality is often not explicit Roche standard AE form: Reporter selects `related, `not related `unknown or `not provided for each drug-event pair. Interpretation of `related is left to the reporter Spontaneously reported events are considered related, for the purpose of case processing and regulatory reporting, unless reporter says `not related Study case reports Investigator codes events as related or not related to the study drug Some instruction for the investigator are provided in the study protocol SUSAR: `Reaction implies `related
5 Instructions for investigators Typical study protocol provides information like this: Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an adverse event is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration: Temporal relationship of event onset to the initiation of study drug Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or re-introduction of study drug (where applicable) Known association of the event with the study drug or with similar treatments Known association of the event with the disease under study Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event Presence of non treatment-related factors that are known to be associated with the occurrence of the event
6 Standard SAE Report Form Causality information
7 Case processing Study cases
8 Serious unexpected events in randomized trials What if the patient is taking placebo? General principles: When assigning causality (e.g. for SUSARs), the investigator should assume that the patient is on the study treatment Aim to preserve blinding where possible. Unblind in emergencies only Submit SUSAR report regardless of actual treatment Investigators and sponsor receive blinded SUSAR reports If unblinded+placebo, no SUSAR report is submitted to authorities DSMBs may request unblinded data, while investigator and patient remain blinded
9 Adding `events to the reporter s original list `Events may be added by the company to the reporter s original list, where there are additional symptoms, signs, other medical conditions etc. described in the original fax/ the free text section of the report form the `past history or `concurrent illness section, unless clearly consistent with the reported diagnosis Interpretation of these events is sometimes difficult May not have been of concern to the reporter No `causality information provided by the reporter
10 Reporter s causality assessment Example: One drug, 12 month period Events from study cases: 568/2155 (26%) `not related (2 re-assigned `related by the company) 944/2155 (44%) `related 643/2155 (30%) no reporter causality assessment Events from spontaneous cases: 199/2681 (8%) `not related 1191/2681 (44%) `related 1291/2681 (48%) no reporter causality assessment Note: All spontaneous events are considered `related by the company for reporting purposes
11 Methods for the assessment of individual cases Guidance CIOMS VI (2005): Survey of pharmaceutical companies: 12/21 companies use `introspection, 2 home-grown algorithms, 3 published methods, 4 non- specific methods Recommendations: Binary yes/no causality (i.e. related/not related) for study investigators Grades of causality (e.g. `possible, `probable, `definite ) offer little practical advantage. Only `related versus `unrelated is needed for regulatory reporting requirements Poor inter-rater agreement using terms such as `possible or `probable Investigator should complete a checklist of potential causes Events should be considered related if there is a reasonable possibility of a causal relationship rather than if a causal relationship cannot be ruled out
12 When should an event be considered `related? Guidance FDA (2010) Investigators/sponsors were too cautious in their interpretation of reasonable possibility. They submitted reports for events that were likely to be manifestations of disease, common, probably unrelated events, or study endpoints. FDA received too many SUSAR reports for which there was no evidence of `relatedness. Document provides guidance and examples to illustrate evidence to suggest a causal relationship between the drug and the event. EMA guideline (2012) For regulatory reporting purposes, all spontaneous reports are considered suspected adverse reactions unless the reporters specifically state they believe the events to be unrelated (page 5)
13 Naranjo algorithm at Roche Pre-2001 Home-made algorithm with 6 categories Used to `triage cases for immediate physician review Events from study cases with score 5 `upgraded to `related for regulatory reporting 2009 Naranjo withdrawn Physicians review all cases Events classified `unrelated or `related for regulatory reporting
14 Naranjo algorithm at Roche Survey of cases scored over a 2 year period : Study cases: 43 causality `upgraded because score 5 Spontaneous cases: 12 causality `upgraded because score 5 We now assume `related for all spontaneously reported events unless reporter explicitly states `not related Perceived limitations Little added value Time consuming (strictly, requires a review of previous cases) Information needed to assess probability of a causal relationship depends on the drug-event pair in question (i.e. not the same for all DEPs)
15
16 Expressing causality in words `Problem expressions A causal association cannot be ruled-out A causal association can never be ruled-out by an individual case. It is possible that the event was caused by Drug X Possible has many shades of meaning. Insufficient information for an adequate assessment Often true, but for certain drug-event pairs, no additional information will help assess causality. ICSR is not necessarily helpful for all drug-event pairs. The case was confounded by Risk factors/alternative explanations are not necessarily confounders
17 Assessment of potential new adverse drug reactions Hypothesis (may be a case report, publication etc.) +/- review of other cases? `Drug Safety Report (includes detailed review all relevant information)? Presentation to the Drug Safety Committee -> Decision concerning risk management (including label update etc.) -> Request for additional information etc.
18 Combining evidence from different sources Examples Mechanism of drug action Effects of similar molecules In vitro data Animal studies Pharmacokinetics Clinical trials Observational studies, claims databases etc. Individual case reports
19 Presenting information to the Drug Safety Committee Bradford Hill criteria Austin Bradford Hill. The Environment and Disease: Association or Causation? Proc Royal Soc Med 1965; 58,
20 Single compelling case reports In some instances, one or two case reports can provide compelling evidence of causality, sufficient to change the product label, risk management etc. Examples Progressive multifocal leukoencephalopathy Stevens Johnson syndrome (single case) Fatal anaphylaxis (single case) See also: Anecdotes that provide definitive evidence. Aronson JK, Hauben M. BMJ 2006;333;
21 Conclusions Structured causality assessment methods for individual cases have been used to facilitate case processing rather than to reach definitive conclusions Naranjo algorithm proved to be generally unhelpful Events are considered `related or `not related for the purpose of case processing and regulatory reporting Definitive decisions about causality (leading to RMP/label changes etc.) usually incorporate evidence from various sources Structured approaches e.g. Bradford Hill criteria No single `once size fits all approach Individual case reports sometimes provide compelling evidence of causality
22 Final thoughts Communicating risk (probabilities) to the patient and prescriber Drug attributable risk, effect of time, etc. Listening to the reporter Why do you think the drug caused the event?
23 References Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333; Bradford Hill A. The Environment and disease: association or causation? Proc Royal Soc Med 1965; 58, Naranjo CA, Busto U, Sellers EM, Sandor P et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): Taofikat B. Agbabiaka TB, Savovi J, Ernst E. Methods for causality assessment of adverse drug reactions. A systematic review. Drug Safety 2008; 31 (1): Guidelines for preparing core clinical safety information on drugs. 2 nd Ed. Report of CIOMS Working Groups III and IV. CIOMS Geneva 1999 Management of safety information from clinical trials. Report of CIOMS Working Group VI. CIOMS Geneva 2005 EMA: Guideline on good pharmacovigilance practices (GVP); Module IV Management and reporting of adverse reactions to medicinal products, 20 February 2012; EMA/873138/2011 FDA: Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Sep Drug Safety FDA: Federal Register/Vol75, No 188/Wednesday, September 29, 2010/Rules and Regulations p59945
24 Back-up slides, additional references etc.
25 Guidance Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Sep Drug Safety FDA found that investigators/sponsors were too cautious in their interpretation of reasonable possibility. They submitted reports for events that were likely to be manifestations of disease, common, probably unrelated events, or study endpoints. FDA received too many SUSAR reports for which there was no evidence of `relatedness. Federal Register/Vol75, No 188/Wednesday, September 29, 2010/Rules and Regulations p59945 Examples to illustrate `evidence to suggest a causal relationship between the drug and the adverse event for reporting purposes A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g. angioedema, hepatic injury, SJS) One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g. tendon rupture) An aggregate analysis of specific events observed in trials (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy), that indicates those events occur more frequently in the drug treatment group than in a concurrent or historic control group
26 Guidance CIOMS VI A CRF is never likely to contain all the fields needed to evaluate causality for all possible types of adverse event (p82) Pre-study training of investigators is very important (p82) Causality assessment for individual SAEs is more relevant for determining regulatory reporting status than for clinical analysis (p120) CIOMS III/V Recommends against expressions in the product label such as The following have been reported, but a causal relationship has not been established, but recognizes some possible advantages to such an approach (p25) Good quality information is essential (p30) The threshold (strength of evidence required) may differ according to the nature and seriousness of the event (p30) No quantitative criteria (such as risk difference >5%) p56 Investigators should always be strongly encouraged to express their opinion on what the cause of an event might be (p56)
27 Guidance ICH E2A ICH E2B The term `adverse reaction implies at least a reasonable possibility of a causal relationship between a suspected product and an adverse event Spontaneously reported events should be considered `related for the purpose of regulatory reporting
28 Capturing the reporter s assessment of causality Proposal #1 Note: Probability categories derived from: Rockey DC, Seeff LB, Rochon J, Freston J et al. for the US Drug-Induced Liver Injury Network. Causality assessment in druginduced liver injury using a structured expert opinion process: Comparison to the roussel-uclaf causality assessment method. Hepatology 2010; 51:
Guidance for Industry and Investigators
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationPHARMACOVIGILANCE GUIDELINES
PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions
More informationGuidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
More informationTUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011
TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationSafety Assessment for IND Safety Reporting Guidance for Industry
Safety Assessment for IND Safety Reporting Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationMedDRA in clinical trials industry perspective
MedDRA in clinical trials industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationData Management in Clinical Trials
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
More informationAdverse Events: Documenting, Recording, and Reporting
Adverse Events: Documenting, Recording, and Reporting Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Introduction Monitoring of adverse
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationRisk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationPOST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationOptimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation;
More informationEphMRA Adverse Event Reporting Guidelines 2013
EphMRA Adverse Event Reporting Guidelines 2013 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationMedDRA in pharmacovigilance industry perspective
MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
More informationLearn More About Product Labeling
Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific
More informationGuidance notes on the management of adverse events and product complaints from digital media
Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media ABPI Pharmacovigilance
More informationTEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationCDISC Data Standards Can Facilitate Composition of Adverse Event Narratives
CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives Anisa Scott, Ph.D. and Richard C. Zink, Ph.D. JMP Life Sciences SAS Institute, Inc. anisa.scott@jmp.com Copyright 2010 SAS Institute
More informationStakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,
More informationGuidance for Industry
Guidance for Industry E2F Development Safety Update Report U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationWorkshop on Patient Support and Market Research Programmes
Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations
More informationEphMRA Adverse Event Reporting Guidelines 2015
EphMRA Adverse Event Reporting Guidelines 2015 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationVersion history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
More informationElectronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety)
Pharmacovigilance information for pharmaceutical companies Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety) This document
More informationICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5
European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:
More informationGuidance on adverse drug reactions
Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system
More informationYOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy
YOUR GATEWAY TO EXPERIENCE, quality & FLEXIBILITy DATA MANAGEMENT SERVICES The quality of your data defi ne the success of your trial, therefore proper handling of data is fundamental. Our Data Management
More informationE2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers
E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report & Current version dated 31 March International Conference on Harmonisation of Technical Requirements
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
More informationHow To Write A Dsur
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEVELOPMENT SAFETY UPDATE REPORT E2F Current Step
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationOBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Opportunities for Signal Detection in an Active Surveillance System Andrew Bate Pfizer, Senior Director, Analytics Team Lead Epidemiology OMOP January 2011 Symposium Contents Background Signal
More informationMedical Dictionary for Regulatory Activities (MedDRA) Update
Medical Dictionary for Regulatory Activities (MedDRA) Update International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Topics MedDRA as an ICH
More informationThe use of the WHO-UMC system for standardised case causality assessment
The use of the WHO-UMC system for standardised case causality assessment Why causality assessment? An inherent problem in pharmacovigilance is that most case reports concern suspected adverse drug reactions.
More informationSALUS: Enabling the Secondary Use of EHRs for Post Market Safety Studies
SALUS: Enabling the Secondary Use of EHRs for Post Market Safety Studies May 2015 A. Anil SINACI, Deputy Project Coordinator SALUS: Scalable, Standard based Interoperability Framework for Sustainable Proactive
More informationEUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY
EUROPEAN MEDICINES AGENCY DRUG SAFETY PRACTICES AND TOOLS Henry Fitt, Kevin Blake, Xavier Kurz Pharmacovigilance & Risk Management European Medicines Agency, London Contents Eudravigilance & Signal Detection
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationQuality Monitoring Checklist
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationGUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON
More informationGuidance for the format and content of the protocol of non-interventional post-authorisation safety studies
26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation
More informationAn Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods
An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods In considering the safety of chemicals added to foods, or present in foods due to environmental circumstances, we
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationGuideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
More informationICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER)
April 2012 EMA/CHMP/ICH/544553/1998 Committee for medicinal products for human use (CHMP) ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER) Step 3 Transmission to CHMP 16 April 2012
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationGuidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted to ERMS FG 19
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationThe Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial
The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial In this white paper, we will explore the consequences of missing data in the ATLAS ACS 2-TIMI 51 Trial and consider if an alternative approach
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationEudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
More informationGood practice guide on recording, coding, reporting and assessment of medication errors
1 2 3 14 April 2015 EMA/762563/2014 Pharmacovigilance Risk Assessment Committee (PRAC) 4 5 6 Good practice guide on recording, coding, reporting and assessment of medication errors Draft Draft finalised
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationThe Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
More informationQuestions and Answers to the Annual Safety Report
Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit
More informationDetailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Pharmacovigilance costs 0.12%-0.22% of hospital admissions
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
More informationClinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group
Clinical Trial Protocol Development Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group Objectives The clinical trial protocol is the heart of any
More informationIOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
More informationSafety Monitoring in Clinical Trials
Pharmaceutics 2013, 5, 94-106; doi:10.3390/pharmaceutics5010094 OPEN ACCESS pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Article Safety Monitoring in Clinical Trials Bin Yao *, Li Zhu,
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationIntroduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationGlossary of terms used in Pharmacovigilance
Glossary of terms used in Pharmacovigilance Absolute risk Risk in a population of exposed persons; the probability of an event affecting members of a particular population (e.g. 1 in 1,000). Absolute risk
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationGuideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)
London, 21 April 2009 Doc. Ref. EMA/13432/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports
More informationGuidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
More informationFor purposes of this policy, "medication" means any prescription drug or over-the-counter medicine or nutritional supplement.
5330/Page 1 of 5 M 5330 The Board of Education disclaims any and all responsibility for the diagnosis and treatment of the illness of any pupil. At the same time, the Board recognizes that a pupil's attendance
More informationABSTRACT INTRODUCTION PATIENT PROFILES SESUG 2012. Paper PH-07
Paper PH-07 Developing a Complete Picture of Patient Safety in Clinical Trials Richard C. Zink, JMP Life Sciences, SAS Institute, Cary, NC, United States Russell D. Wolfinger, JMP Life Sciences, SAS Institute,
More informationUse of Antidepressants in Nursing Home Residents. A Joint Statement of the Members of the Long Term Care Professional Leadership Council (LTCPLC)
Use of Antidepressants in Nursing Home Residents Item 1L A Joint Statement of the Members of the Long Term Care Professional Leadership Council (LTCPLC) SUMMARY The LTCPLC wishes to provide information
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More information